Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2019 Oct 3;19(1):147–156. doi: 10.1158/1535-7163.MCT-18-1202

Figure 4. Concomitant inhibition of the angiopoietin-TIE2 axis and the MET kinase pathway in RP-R-02LM tumors (Orthotopic study) yields significant alterations in pro-tumor macrophages.

Figure 4.

(A) Single stain and merge of TIE2+ (blue) M2-like, tumor promoting macrophages (CD206+F4/80+ - green/red) reveals a significant reduction in the presence of M2-like tumor associated macrophages in the combination treatment cohort. Scale bar= 400 μm (B) TIE2+CD206+ co-localization indicates the potential for combination treatment to directly impact the presence of TAMs in the tumor microenvironment. Spearman’s correlation coefficient for all treatment groups ≈ 0.9. Spearman’s correlation coefficient was calculated by using imageJ coloc2 across different treatment conditions. (C, D, E) Blinded quantitation of the immunofluorescent staining reveals a statistically significant reduction in TAMs (TIE2+F4/80+CD206+) in the tumor microenvironment. (n = 30–40 images per group).